FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2763081391> ?p ?o ?g. }

• W2763081391 endingPage "3713" @default.
• W2763081391 startingPage "3706" @default.
• W2763081391 abstract "Purpose Enhancer of zeste homolog 2 (EZH2), a chromatin remodeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC). However, the effect of EZH2 on outcomes in localized ccRCC is unclear, and molecular biomarkers are not currently integrated into prognostic models or adjuvant therapy trials. Methods We performed Cox regression to evaluate the association of tumor-based EZH2 gene and protein expression with survival in three independent cohorts: a cohort from The Cancer Genome Atlas (n = 532), a cohort from University of Texas Southwestern Medical Center (n = 122), and a cohort from Mayo Clinic (n = 1,338). Analyses were adjusted for the prognostic stage, size, grade, and necrosis (SSIGN) score as well as within low-, intermediate-, and high-risk SSIGN groups. Results Patients in The Cancer Genome Atlas cohort with EZH2-high gene expression were 1.5 times more likely to experience overall death than patients with EZH2-low expression (95% CI, 1.1 to 2.3; P = .028). Patients in the University of Texas Southwestern Medical Center cohort with EZH2-high protein expression were two times more likely to experience overall death than patients with EZH2-low expression (95% CI, 1.1 to 4.4; P = .034). Similarly, patients in the Mayo Clinic cohort with EZH2-high protein expression were 1.4 times more likely to experience overall death (95% CI, 1.2 to 1.7; P < .001). Patients in the Mayo Clinic cohort with EZH2-high protein expression were nearly two times more likely to experience RCC-specific death (95% CI, 1.5 to 2.6; P < .001); EZH2 protein expression was particularly prognostic among patients with low-risk SSIGN tumors (HR, 6.1; 95% CI, 3.4 to 11.1; P < .001). Conclusion EZH2 expression accurately predicts risk of RCC death beyond existing clinicopathologic models, particularly in low- and intermediate-risk SSIGN tumors. Further studies are required to incorporate molecular biomarkers into surveillance guidelines and adjuvant clinical trials." @default.
• W2763081391 created "2017-10-20" @default.
• W2763081391 creator A5018252851 @default.
• W2763081391 creator A5033771723 @default.
• W2763081391 creator A5034715033 @default.
• W2763081391 creator A5040267170 @default.
• W2763081391 creator A5040994175 @default.
• W2763081391 creator A5046541559 @default.
• W2763081391 creator A5058379826 @default.
• W2763081391 creator A5058650905 @default.
• W2763081391 creator A5067883322 @default.
• W2763081391 creator A5069595062 @default.
• W2763081391 creator A5082156719 @default.
• W2763081391 creator A5082725102 @default.
• W2763081391 date "2017-11-10" @default.
• W2763081391 modified "2023-10-07" @default.
• W2763081391 title "Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma" @default.
• W2763081391 cites W1509042831 @default.
• W2763081391 cites W1520140649 @default.
• W2763081391 cites W1524165063 @default.
• W2763081391 cites W1558134527 @default.
• W2763081391 cites W1968657935 @default.
• W2763081391 cites W1971712350 @default.
• W2763081391 cites W1992142098 @default.
• W2763081391 cites W1995235833 @default.
• W2763081391 cites W2026195108 @default.
• W2763081391 cites W2034217913 @default.
• W2763081391 cites W2061812825 @default.
• W2763081391 cites W2092892924 @default.
• W2763081391 cites W2097096070 @default.
• W2763081391 cites W2097900396 @default.
• W2763081391 cites W2100630390 @default.
• W2763081391 cites W2104611467 @default.
• W2763081391 cites W2108676874 @default.
• W2763081391 cites W2109388391 @default.
• W2763081391 cites W2114354078 @default.
• W2763081391 cites W2129925362 @default.
• W2763081391 cites W2150575159 @default.
• W2763081391 cites W2152874907 @default.
• W2763081391 cites W2163814095 @default.
• W2763081391 cites W2165482913 @default.
• W2763081391 cites W2168403132 @default.
• W2763081391 cites W2171369497 @default.
• W2763081391 cites W2207587871 @default.
• W2763081391 cites W2208351915 @default.
• W2763081391 cites W2293077587 @default.
• W2763081391 cites W2320983896 @default.
• W2763081391 cites W2513249090 @default.
• W2763081391 cites W2530419161 @default.
• W2763081391 doi "https://doi.org/10.1200/jco.2017.73.3238" @default.
• W2763081391 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5678341" @default.
• W2763081391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28976794" @default.
• W2763081391 hasPublicationYear "2017" @default.
• W2763081391 type Work @default.
• W2763081391 sameAs 2763081391 @default.
• W2763081391 citedByCount "32" @default.
• W2763081391 countsByYear W27630813912018 @default.
• W2763081391 countsByYear W27630813912019 @default.
• W2763081391 countsByYear W27630813912020 @default.
• W2763081391 countsByYear W27630813912021 @default.
• W2763081391 countsByYear W27630813912022 @default.
• W2763081391 countsByYear W27630813912023 @default.
• W2763081391 crossrefType "journal-article" @default.
• W2763081391 hasAuthorship W2763081391A5018252851 @default.
• W2763081391 hasAuthorship W2763081391A5033771723 @default.
• W2763081391 hasAuthorship W2763081391A5034715033 @default.
• W2763081391 hasAuthorship W2763081391A5040267170 @default.
• W2763081391 hasAuthorship W2763081391A5040994175 @default.
• W2763081391 hasAuthorship W2763081391A5046541559 @default.
• W2763081391 hasAuthorship W2763081391A5058379826 @default.
• W2763081391 hasAuthorship W2763081391A5058650905 @default.
• W2763081391 hasAuthorship W2763081391A5067883322 @default.
• W2763081391 hasAuthorship W2763081391A5069595062 @default.
• W2763081391 hasAuthorship W2763081391A5082156719 @default.
• W2763081391 hasAuthorship W2763081391A5082725102 @default.
• W2763081391 hasBestOaLocation W27630813911 @default.
• W2763081391 hasConcept C104317684 @default.
• W2763081391 hasConcept C121608353 @default.
• W2763081391 hasConcept C126322002 @default.
• W2763081391 hasConcept C143998085 @default.
• W2763081391 hasConcept C150194340 @default.
• W2763081391 hasConcept C167135981 @default.
• W2763081391 hasConcept C2777472916 @default.
• W2763081391 hasConcept C2781278892 @default.
• W2763081391 hasConcept C50171091 @default.
• W2763081391 hasConcept C502942594 @default.
• W2763081391 hasConcept C50382708 @default.
• W2763081391 hasConcept C54355233 @default.
• W2763081391 hasConcept C71924100 @default.
• W2763081391 hasConcept C72563966 @default.
• W2763081391 hasConcept C86803240 @default.
• W2763081391 hasConceptScore W2763081391C104317684 @default.
• W2763081391 hasConceptScore W2763081391C121608353 @default.
• W2763081391 hasConceptScore W2763081391C126322002 @default.
• W2763081391 hasConceptScore W2763081391C143998085 @default.
• W2763081391 hasConceptScore W2763081391C150194340 @default.
• W2763081391 hasConceptScore W2763081391C167135981 @default.
• W2763081391 hasConceptScore W2763081391C2777472916 @default.

• next